Reliance Life Sciences (RLS), part of India’s largest conglomerate, is expected to start a phase I clinical study from the original Covid-19 vaccine, report Rupali Mukherjee.
The subject expert committee, which suggested drug regulators on vaccines and new drugs, reviewing the company’s applications and learned to recommend it for approval on Thursday.
The formal nod to conduct a trial from the two doses is expected for the next few days, said the source to Ti.
The vaccine that is being developed is a covid-19 vaccine based on recombinant protein protein, and is expected to be launched in the first quarter of 2022.
The company began the development process last year, with a vaccine that entered the pre-clinical stage in the October vaccine was developed at the Navi Mumbai company, and is expected “Competitive price”.
Reliance Life Sciences Finds a Nod for Vaccine Trials
